The University of Texas System

Johns Hopkins University

Apollo Endosurgery, Inc.

Olympus Corporation

Boston Scientific Scimed, Inc.

Other

Leland Stanford Junior University

Lieber Institute, Inc.

Neurogastrx, Inc.

Mayo Foundation for Medical Education and Research

Olympus Optical Company, Ltd.

Biotex, Inc.

Chek-med Systems, Inc.

Cryomedical Sciences Inc.

Pasricha, Pankaj Jay

Pankaj Jay Pasricha

Jiande Chen

Yoshio Onuki

Koichi Kawashima

Vladimir Mitelberg

Donald K Jones

Takayuki Suzuki

Satoshi Miyamoto

Brett E Naglreiter

James C Barrow

Yifang Huang

Anthony Nicolas Kalloo

Youseph Yazdi

David Y Yuan

Cyril De Colle

Keita Suzuki

Tetsuya Yamamoto

Ryan V Wales

Nicholas James Durr

Sritam Parashar Rout

Christopher John Gostout

Ashish Nimgaonkar

Amir Hossein Soltanianzadeh

Anthony Nicholas Kalloo

Marc Chelala

Maria F Torres

David M Gullotti

Kyle R Cowdrick

Pandu R R Gangula

Sergey Veniaminovich Kantsevoy

Ashok Gowda

Roger J McNichols

John Thomas Favreau

Yuji Sakamoto

Masahiro Ishikawa

Hideki Shimonaka

Tsuyoshi Tsukagoshi

Massoud Motamedi

Sydney Sheung Chee Chung

Koh Kimura

J Landon Gilkey

Jessica Louise Powers

Amit Banerjee

Chad N Weiler

Maria-Adelaide Micci

Dennis L McWilliams

Simon C Mathews

Demetri Monovoukas

Sungmin R Cho

Jacob Caldwell

John Winston

Mohan Shenoy

Martin Gilbert Pomper

Tsukasa Kobayashi

John G Baust

David Juergen Wustrow

Keiichi Arai

Thomas Henry Jozefiak

Michael Steven Poslusney

George L Coles

Norio Onishi

Lian Liu

Seulki Lee

Kevin Colbert

Yoshihiko Sugi

Magdalena Scully

Michael Parlato

Liansheng Liu

Qian Li

Ingrid Buchler

Alfred Spormann

Joshua Broadwater

Jlande Chen

George Coles

Lawrence Potorff

Maria A Micci

Helen Hellmich

Willemijntje A Hoogerwerf

Trisha Pasricha

Rami Hawari

Ogyi Park

Pratik Patel

Yuji c/o Olympus Corporation Sakamoto

Norio c/o Olympus Corporation Onishi

Yoshio c/o Olympus Corporation Onuki

Satoshi c/o Olympus Corporation Miyamoto

The present disclosure relates generally to the field of medical devices and establishing access to body passageways. In particular, the present disclosure relates to devices, systems and methods to facilitate entry of an endoscopic accessory tool into and/or through patient-specific anatomies. For example, the devices, systems and methods of the present disclosure may transmit mechanical motion to the distal end of an endoscopic accessory tool to facilitate atraumatic access to tortuous or otherwise restricted anatomies.

Devices, systems and methods for transmitting motion to the distal tip of an endoscopic accessory tool

A method for performing a screening includes illuminating a sample with light from a screen of a system at a first wavelength while the system is at a predetermined position with respect to the sample. The method also includes capturing a first image of the sample using a camera of the system while the system is at the predetermined position and the sample is illuminated with the light at the first wavelength. The method also includes illuminating the sample with the light from the screen at a second wavelength while the system is at the predetermined position. The method also includes capturing a second image of the sample using the camera while the system is at the predetermined position and the sample is illuminated with the light at the second wavelength. The method also includes combining the first and second images to produce a multispectral image.

Capturing multi-spectral images

Fluorescent imaging systems for performing an endoscopic procedure, such as a retrograde cholangiopancreatography (ERCP) procedure may include a first light source for emitting light in the visible spectrum, or light in the near infrared (NIR) spectrum, or both. A light source bandpass filter may block the emitted light in the visible spectrum, or in the NIR spectrum, or both. A first sensor may be capable of detecting the light in the visible spectrum, or the light in the NIR spectrum, or both. A sensor bandpass filter may block the detected light in the visible spectrum, or in the NIR spectrum, or both. The first or a second light source, or the first or a second sensor, or combinations thereof, may be removably disposed on a duodenoscope.

Attachment for duodenoscope

A method for detecting a molecule in a sample includes applying a first filter to an image at a first wavelength. The method also includes applying a second filter to the image at a second wavelength. The method also includes applying a third filter to the image at a third wavelength. The first, second, and third wavelengths are within a predetermined wavelength range, and wherein first, second, and third wavelengths are different from one another. The method also includes detecting a spectral signature for the molecule in the sample in the image after the first, second, and third filters are applied to the image. The method also includes determining whether the molecule is present in the sample based at least partially upon the detected spectral signature.

Camera-based hemoglobin detection

Described are methods for treating or preventing IBS in subjects by administering molybdenum or a salt thereof to subjects having or prone of getting IBS. The molybdenum has been shown to treat or prevent IBS in subjects administered this agent when compared to reference subjects not administered molybdenum.

Treatment of irritable bowel syndrome with molybdenum

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof) of formula (I), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activity. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods of using same for the treatment of systemic diseases of the body.

Substituted benzopyrazolo[1,5-a][1,4]diazepines as GABA positive allosteric modulators

The present disclosure relates generally to fluorescent imaging devices, systems, and methods for an endoscopic procedure, and in particular, indocyanine green (ICG) fluorescence. In some embodiments, a device for fluorescent imaging during an endoscopic procedure may include an attachment connectable to a distal end of an endoscope. The attachment may include a first filter alignable with a light source of the endoscope, and a second filter alignable with an imaging device of the endoscope. The first filter may be positionable such that in a first position the first filter is aligned with the light source, and in a second position the first filter is out of alignment with the light source. The second filter may be positionable such that in a first position the second filter is aligned with the imaging device, and in a second position the second filter is out of alignment with the imaging device.

Fluorophore imaging devices, systems, and methods for an endoscopic procedure

Provided herein are methods, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and/or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.

Methods for treating GI tract disorders

The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-brain barrier. The compounds and compositions of the present invention are useful for treatment of diseases or disorders which are mediated by GABA-A neuronal activity, such as, for example, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance.

Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system

The present invention provides compositions and methods for treatment of metabolic syndromes. Namely, the presently disclosed compositions and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic disorders. The compositions include components for forming luminal barriers within the gastrointestinal tract of a subject where the barrier is created in-situ via interaction of resident mucin with the mucin-interacting agent.

Composition and method for treatment of metabolic disorders

Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL), its analogues, and anti-DR5 agonistic antibodies. In certain embodiments, TRAIL analogs and anti-death receptor 5 agonistic antibodies have analgesic and disease modifying effects on the pancreas.

Compositions and methods for treating pancreatitis and pain with death receptor agonists

Growing community of inventors

Houston, TX, United States of America

Pankaj Jay Pasricha